Business Context and Reporting Period
This Form 8-K filing by Minerva Neurosciences, Inc. (NERV) is dated June 16, 2023. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative metric disclosed is the Market Value of Listed Securities (MVLS), which must be maintained at $35 million or greater to satisfy Nasdaq Listing Rule 5550(b)(2).
Material Changes
The primary material change is the resolution of a delisting threat. On December 1, 2022, the company was notified of non-compliance due to an MVLS below $35 million for 30 consecutive business days. Although a hearing was scheduled for May 31, 2023, to address continued non-compliance, the company subsequently maintained an MVLS of $35 million or greater for ten consecutive business days. Consequently, Nasdaq determined the company has regained compliance, and the scheduled hearing was cancelled.
Outlook and Risks
The company's securities will continue to be listed and traded on Nasdaq. The immediate risk of delisting from The Nasdaq Capital Market has been mitigated by regaining compliance with the MVLS requirement. No other risks, contingencies, or unusual items are detailed in this specific filing.
Investor Verification Points
- Verify the current Market Value of Listed Securities (MVLS) to ensure it remains above the $35 million threshold.
- Confirm the continued listing status of NERV on The Nasdaq Capital Market.
- Review prior filings for the financial performance and cash position that influenced the MVLS decline in late 2022.